Pharmacological Studies of the Acute and Chronic Effects of (+)-3,4-Methylenedioxymethamphetamine on Locomotor Activity: Role of 5-Hydroxytryptamine1A and 5-Hydroxytryptamine1B/1D Receptors
A. C. McCreary, M. G. Bankson, K. Cunningham
Journal of Pharmacology and Experimental Therapeutics September 1, 1999 DOI: 10.1016/s0022-3565(24)34994-8 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Experimental animal study Peer reviewed |
|---|---|
| Population | Rats |
| Interventions | (1)-MDMA GR 127935 WAY 100635 |
| Dose | (1)-MDMA 3 mg/kg; GR 127935 0.1, 0.3, 0.625, 1.25, and 2.5 mg/kg; WAY 100635 0.5–2 mg/kg |
| Duration | 5 days of treatment |
| Topics | MDMA |
| Key findings | GR 127935 blocked (1)-MDMA-induced peripheral and central activity, and WAY 100635 had little effect apart from enhanced central activity at 0.5 mg/kg. Central activity increased from day 1 to day 5 of repeated (1)-MDMA, while rats pretreated daily with GR 127935 (2.5 mg/kg) showed significant increases in peripheral, central, and rearing activity. |
Abstract
Activity in the periphery and center of an open field as well as rearing activity were measured in photobeam monitors. (1)-MDMA-induced peripheral and central activities were blocked by GR 127935 (0.3, 0.625, 1.25, and 2.5 mg/kg); central hyperactivity was blocked by 0.1, 0.3, and 0.625 mg/kg GR 127935. WAY 100635 (0.5–2 mg/kg) had little effect on (1)-MDMA-induced activity except for an enhancement of central activity at one dose (0.5 mg/kg). Central activity induced by (1)-MDMA increased from day 1 to day 5 of treatment with (1)-MDMA (3 mg/kg), whereas peripheral, central, and rearing activity significantly increased in (1)-MDMA-treated rats pretreated daily with GR 127935 (2.5 mg/kg).
Comparable studies
Other preclinical and animal studies on MDMA, most cited first.
Citations in the library
Cited by 37
- Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies Human Psychopharmacology: Clinical and Experimental December 1, 2001
- Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms Pharmacological Reviews December 16, 2020
- Acute Psychological and Neurophysiological Effects of MDMA in Humans Journal of Psychoactive Drugs June 1, 2002
- Sex differences and serotonergic mechanisms in the behavioural effects of psilocin Behavioural Pharmacology October 13, 2015
- Serotonin–GABA interactions modulate MDMA‐induced mesolimbic dopamine release Journal of Neurochemistry October 27, 2004
and 32 more in the library
Cites 13
- The molecular mechanism of "ecstasy" [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proceedings of the National Academy of Sciences March 1, 1992
- Amphetamine derivatives induce locomotor hyperactivity by acting as indirect serotonin agonists. Psychopharmacology 1991
- Examination of the action of 3,4-methylenedioxymethamphetamine on rat A10 dopamine neurons Synapse May 1, 1996
- Methylenedioxymethamphetamine-induced inhibition of neuronal firing in the nucleus accumbens is mediated by both serotonin and dopamine. Neuroscience September 1996
- Effects of the selective 5-HT2A receptor antagonist MDL 100,907 on MDMA-induced locomotor stimulation in rats. Neuropsychopharmacology August 1996
and 8 more in the library